Distribution of consolidation therapies (third cycle of chemotherapy, autologous SCT, or allo-SCT), applied to patients in donor and no donor groups
| Type of therapy . | Group of patients . | |
|---|---|---|
| Donor . | No donor . | |
| All patients | 326 | 599 |
| Chemotherapy, n (%)* | 55 (17) | 398 (65) |
| Autologous SCT, n (%)† | 3 (1) | 165 (28) |
| Allogeneic SCT, n (%)† | ||
| HLA-identical sibling | 268 (82) | 0 |
| Unrelated donor | 0 | 40 (7) |
| Mismatched family donor | 0 | 5 (1) |
| Type of therapy . | Group of patients . | |
|---|---|---|
| Donor . | No donor . | |
| All patients | 326 | 599 |
| Chemotherapy, n (%)* | 55 (17) | 398 (65) |
| Autologous SCT, n (%)† | 3 (1) | 165 (28) |
| Allogeneic SCT, n (%)† | ||
| HLA-identical sibling | 268 (82) | 0 |
| Unrelated donor | 0 | 40 (7) |
| Mismatched family donor | 0 | 5 (1) |
SCT indicates stem cell transplantation; HLA human leukocyte antigen.
*Third cycle of chemotherapy.
†Preceded by high-dose cytotoxic therapy.